DiaMedica Therapeutics Inc (DMAC)

NASDAQ

$7.01

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.

Website: https://www.diamedica.com

Sector:

Healthcare

Industry:

Biotechnology

68 analysts

Buy

Target: $15.50 (+121.11%)

Market Cap

$412M

FCF 5Y CAGR

+24.03%

Free Cash Flow Yield

-7.54%

Beta (5Y)

1.21

Price Chart

Adjust inflation

Log

Valuation

Market Cap$412M

P/S66.68

P/B8.48

Profitability

EBITDA-$37M

EPS-$0.69

Financial Health

Free Cash Flow Yield-7.54%

Growth & Risk

EPS 5Y CAGR-1.88%

FCF 5Y CAGR+24.03%

Beta (5Y)1.21

Sharpe Ratio1.15